| long-term immunity and immune response to a booster dose following vaccination with the inactivated japanese encephalitis vaccine ixiaro, ic51. | ic51 (ixiaro, jespect) is a recently approved prophylactic japanese encephalitis virus vaccine with a two-vaccine primary immunization regimen. in this phase 3 trial, after primary immunization with a day 0/28 dose schedule, seroprotection rates were 83%, 58% and 48% at month 6, month 12 and month 24, respectively. a booster dose at month 11 and/or month 23 in subjects with neutralizing antibody titers below the limit of detection (defined as a serum dilution giving a 50% reduction of plaque cou ... | 2010 | 20541581 |